摘要
目的:观察替加环素治疗多重耐药鲍曼不动杆菌(MDRAB)感染的临床疗效。方法:选取78例腹腔手术术后发生多重耐药鲍曼不动杆菌感染的临床病例作为观察对象,分为碳青霉烯类抗生素组(A组)40例、替加环素组(B组)38例;治疗疗程平均2周。每组患者在年龄、性别、基础疾病等方面差异无统计学意义。观察2组患者的细菌学疗效、临床疗效的变化以及安全性评价。结果:A组临床有效率57.50%,细菌清除率52.50%;B组临床有效率71.05%,细菌清除率68.42%,A、B两组组间比较、组内比较差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论:替加环素对MDRAB导致感染具有良好的临床疗效及安全性,可作为此类细菌感染临床用药的选择。
Objective：To observe the clinical efficacy of tigecycline in treatment of infections caused by multidrugresistant acinetobacter baumannii. Methods： A total of 78 cases of abdominal infections caused by multidrugresistant Acinetobacter baumannii were retrospectively studied.The patients were divided into the carbapenems group（group A） of 40 cases and the tigecycline group（group B） of 38 cases. The course were about 2 weeks on average. There were no statistical difference in the age, gender, or underlying diseases between the two groups. The bacteriological effect, the therapeutic effect and safety evaluation were observed and compared between the two groups.Results： The clinical effective rate was 57.50% in the carbapenems group and 71.05% in the tigecycline groups. The bacterial eradication rate was 49.51% in the carbapenems group and 68.37% in the tigecycline groups.The differences between the two groups were significant.The severe adverse reactions were not discovered in the two groups. Conclusion： The tigecycline can achieve good clinical therapeutic effect on abdominal infections caused by multidrugresistant Acinetobacter baumannii and could be promoted in the hospital.
出处
《天津医科大学学报》
2015年第2期164-167,共4页
Journal of Tianjin Medical University
关键词
替加环素
多重耐药鲍曼不动杆菌
抗菌药物
腹腔感染
tigecycline
multidrugresistant Acinetobacter baumannii
antibacterial agents
abdominal infection
